Tesamorelin benefits:
visceral fat, IGF-1, body composition.

The most clinically established tesamorelin benefit is a substantial and selective reduction in visceral adipose tissue — the deep abdominal fat that surrounds internal organs and drives most of the cardiometabolic risk associated with central obesity. In the Falutz Phase III trials published in the New England Journal of Medicine (2007 and 2010), daily 2 mg subcutaneous tesamorelin produced a mean VAT reduction of 15.2% at 26 weeks and 18% at 52 weeks of continuous treatment. Placebo patients showed no change.

Importantly, the tesamorelin peptide benefit is specific to visceral fat — subcutaneous fat (the softer fat directly under the skin) was affected much less. This selective VAT effect is why tesamorelin was developed as a body-composition therapy rather than a weight-loss drug. The mechanism underlying this selectivity is that visceral adipocytes express higher densities of GH receptors than subcutaneous adipocytes, so the pulsatile GH release triggered by tesamorelin preferentially mobilizes visceral fat stores through hormone-sensitive lipase activation.

The clinical importance of VAT-specific reduction is substantial. Visceral fat is a metabolically active tissue that secretes inflammatory cytokines, drives insulin resistance, and correlates with cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver disease. A 15–20% reduction in VAT over 26 weeks is a magnitude of change comparable to significant surgical or pharmacologic interventions, achieved through a mechanism that preserves natural endocrine signaling. For a detailed breakdown of the visceral fat mechanism and VAT-specific biology, see the tesamorelin for visceral fat guide.

A second major tesamorelin benefit emerged from the 2014 JAMA study by Stanley et al., which examined tesamorelin in patients with HIV who also had non-alcoholic fatty liver disease (NAFLD). Over 12 months of daily 2 mg tesamorelin, MRI-measured hepatic fat fraction decreased by a mean of 32% — a reduction of clinical significance in a disease that currently has no FDA-approved pharmacologic therapy specifically targeting liver fat.

The liver fat reduction is mechanistically coherent with the visceral fat finding: ectopic fat accumulation (liver, pancreas, muscle) shares metabolic pathways with visceral adipose tissue, and the GH axis regulates hepatic lipid metabolism directly. By triggering pulsatile GH secretion, tesamorelin peptide increases hepatic lipid oxidation and reduces de novo lipogenesis in hepatocytes — the two primary mechanisms that drive fatty liver accumulation.

This finding has driven growing off-label interest in tesamorelin for metabolic-associated steatotic liver disease (MASLD, the renamed NAFLD) in non-HIV populations. With MASLD now affecting an estimated 30% of adults globally and progressing to MASH (metabolic-associated steatohepatitis) in a significant minority, an effective ectopic-fat-reducing therapy is of significant clinical interest. Tesamorelin remains off-label for this indication outside of HIV-associated populations, but the mechanistic case for benefit is strong.

Tesamorelin produces a sustained elevation of insulin-like growth factor 1 (IGF-1) through its action on pituitary GH release. Clinical trials consistently show IGF-1 rises into the upper half of the age-adjusted physiologic range within the first 2–4 weeks of therapy, and this elevation is maintained throughout continuous dosing. In the Phase III trials, mean IGF-1 increased from baseline by approximately 80–120 ng/mL, a clinically meaningful shift without reaching supraphysiologic levels characteristic of acromegaly.

IGF-1 is the downstream effector for most of GH's anabolic and body-composition effects. Higher physiologic IGF-1 is associated with greater lean body mass, improved protein synthesis, better bone mineral density, and improved skin collagen turnover. The age-related decline in GH secretion — which begins in the early 20s and continues progressively — is reflected in declining IGF-1 levels, and restoring IGF-1 toward younger-adult ranges is the mechanistic rationale for tesamorelin peptide's emerging off-label use as an age-related body composition intervention.

Importantly, because tesamorelin triggers endogenous GH release rather than delivering exogenous GH, the IGF-1 rise is subject to the body's natural feedback mechanisms. Somatostatin — the body's GH-inhibiting hormone — continues to regulate pulse amplitude and prevent runaway GH secretion, which is why IGF-1 elevation with tesamorelin remains physiologic rather than supraphysiologic even on long-term therapy. This is a meaningful safety advantage over direct recombinant GH injection, which bypasses all pituitary feedback.

Beyond visceral fat reduction, tesamorelin produces modest favorable changes in total body composition. In the Phase III trials, mean lean body mass increased by approximately 1.3 kg over 26 weeks, while subcutaneous fat changed minimally. The net effect is body recomposition — lower body fat percentage, higher lean mass ratio — rather than dramatic scale-weight loss.

The lean mass benefit is modest compared to anabolic steroids or supraphysiologic GH therapy, but it is clinically meaningful in the context of aging. Sarcopenia — the age-related loss of lean mass — is associated with functional decline, metabolic deterioration, and increased mortality. A pulsatile GHRH agonist like tesamorelin that preserves or modestly increases lean mass while simultaneously reducing visceral fat produces a favorable body composition trajectory in a single intervention.

Body composition changes from tesamorelin are typically most visible in the abdominal region: waist circumference reduces by 2–4 cm over 26 weeks, sometimes more, while weight scale changes are modest (often just a few pounds). This disconnect between scale and body composition is why DEXA scans, waist measurements, or tape measurements capture tesamorelin benefits more accurately than body weight alone. See the tesamorelin results guide for the full body composition timeline and measurement protocols.

Beyond the primary body composition and metabolic effects, tesamorelin produces a set of secondary benefits characteristic of restored GH pulsatility — benefits that are reported clinically and mechanistically plausible, though less rigorously quantified than VAT reduction in the published literature.

Sleep quality. Deep (slow-wave) sleep is the period of greatest endogenous GH secretion, and chronic sleep restriction is associated with suppressed GH and IGF-1. Restored pulsatile GH signaling from tesamorelin appears to reinforce this relationship, with many patients reporting improved sleep depth, fewer nocturnal awakenings, and better perceived restoration. The mechanism likely involves tesamorelin-induced GH pulses aligning with or augmenting the body's natural nocturnal GH peak.

Recovery and tissue repair. GH and IGF-1 are central mediators of tissue repair, including connective tissue remodeling and muscle recovery after exercise. Tesamorelin peptide use is commonly reported to shorten perceived recovery time after intense training and to improve repair of soft tissue injuries over weeks of therapy. This overlaps with the mechanism of other peptides used for recovery — see the BPC-157 peptide for the regenerative-focused alternative.

Skin quality. Collagen synthesis in skin is partially GH/IGF-1 dependent, and chronic GH decline contributes to thinning dermal collagen with age. Tesamorelin users commonly report modest improvements in skin elasticity and thickness over months of therapy. The effect is slow and cumulative, not dramatic, but consistent with the underlying collagen biology.

Cardiometabolic markers. Phase III data showed improvements in triglyceride levels and total-to-HDL cholesterol ratio on tesamorelin, consistent with the visceral fat reduction — VAT is a major driver of dyslipidemia, so reducing it improves the downstream lipid profile. C-reactive protein (a systemic inflammation marker) also trended downward in the clinical trials, again consistent with reduced visceral adiposity.

Energy and mood. Adult GH deficiency is associated with low energy, low motivation, and mood symptoms, and GH replacement therapy is known to improve these. Tesamorelin, as a GHRH agonist that restores pulsatile GH, appears to produce similar though typically milder benefits in energy and mood in clinical practice. This is not a validated on-label benefit but is a consistent clinical observation.